Search Results - "Sclafani, F"

Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice by Bregni, G., Akin Telli, T., Camera, S., Deleporte, A., Moretti, L., Bali, A.M., Liberale, G., Holbrechts, S., Hendlisz, A., Sclafani, F.

“…•The mainstay of treatment for locally advanced rectal cancer is (chemo) radiotherapy and surgery.•Trials have not given clear indications on the added value…”
Get full text

Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials by Giunta, E.F., Bregni, G., Pretta, A., Deleporte, A., Liberale, G., Bali, A.M., Moretti, L., Troiani, T., Ciardiello, F., Hendlisz, A., Sclafani, F.

“…•TNT is a new standard of care for high-risk stage II and stage III rectal cancers.•Selection of the most appropriate TNT schema should be made on case-by-case…”
Get full text

BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications by Sclafani, F, Gullo, G, Sheahan, K, Crown, J

“…Abstract BRAF is an oncogene encoding a serine–threonine protein kinase involved in the MAPK signalling cascade. BRAF acts as direct effector of RAS and…”
Get full text

Treatment compliance in early-stage anal cancer by Pretta, A., Trevisi, E., Bregni, G., Deleporte, A., Hendlisz, A., Sclafani, F.

Get full text

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer by Sclafani, F., Brown, G., Cunningham, D., Wotherspoon, A., Tait, D., Peckitt, C., Evans, J., Yu, S., Sena Teixeira Mendes, L., Tabernero, J., Glimelius, B., Cervantes, A., Thomas, J., Begum, R., Oates, J., Chau, I.

“…EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal…”
Get full text

Neoadjuvant rectal score: run with the hare and hunt with the hounds by Sclafani, F., Kalaitzaki, E., Cunningham, D., Tait, D., Brown, G., Chau, I.

Get full text

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer by Gullo, G., Zuradelli, M., Sclafani, F., Santoro, A., Crown, J.

Get full text

Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines by Bregni, G., Akin Telli, T., Camera, S., Baratelli, C., Shaza, L., Deleporte, A., Moretti, L., Bali, M.A., Liberale, G., Hendlisz, A., Sclafani, F.

“…•Disagreement between rectal cancer guidelines exists in 62% of relevant topics.•High level of evidence exists for 20% of topics where guidelines are in…”
Get full text

Highlights from the ESMO Annual Meeting 2023 – EORTC GI Tract Group picks from the colorectal and anal cancer track by R. Fazio, D. Arnold, G. Folprecht, M.G. Guren, T. Koessler, L. Wyrwicz, F. Sclafani

Get full text

Microsatellite Instability is associated with Reduced Disease Specific Survival in Stage III Colon Cancer by Mohan, Helen Mary, Ryan, Eanna, Balasubramanian, Ishwaria, Kennelly, Rory, Geraghty, Robert, Sclafani, Francesco, Fennelly, David, McDermott, Ray, Ryan, Elizabeth J, O’Donoghue, Diarmuid, Hyland, John MP, Martin, Sean T, O’Connell, P Ronan, Gibbons, David, Winter, Des, Sheahan, Kieran

“…Abstract Background Up to 15% of colorectal cancers exhibit microsatellite instability (MSI), where errors in replication go unchecked due to defects in the…”
Get full text

InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial by Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov, E., Bryant, A., Peckitt, C., Roy, A., Seymour, M.T., Welch, J., Saunders, M.P., Muirhead, R., Bridgewater, J., Falk, S., Glynne-Jones, R., Arnold, D., Cunningham, D.

Get full text

Current practices and challenges in implementing precision medicine for upper gastrointestinal cancers in European academic centers: an EORTC survey by M. Alsina, A.E. Huerta, F. Lordick, S. Verschueren, M. Moehler, E. Fontana, E. Smyth, F. Sclafani, A.D. Wagner, L. Rimassa, A. Lamarca, C. Neuzillet, R. Obermannová

“…Background: Precision oncology is gaining momentum in managing patients with gastrointestinal cancers. This study examines the implementation of personalized…”
Get full text

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab by Sclafani, F., Roy, A., Cunningham, D., Wotherspoon, A., Peckitt, C., Gonzalez de Castro, D., Tabernero, J., Glimelius, B., Cervantes, A., Eltahir, Z., Oates, J., Chau, I.

“…HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of…”
Get full text

RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial by Sclafani, F, Gonzalez, D, Cunningham, D, Hulkki Wilson, S, Peckitt, C, Giralt, J, Glimelius, B, Roselló Keränen, S, Wotherspoon, A, Brown, G, Tait, D, Oates, J, Chau, I

“…Abstract Background RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We…”
Get full text

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial by Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J.C., Braconi, C., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., Gonzalez De Castro, D., Hulkki Wilson, S., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Valeri, N.

“…Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T >…”
Get full text

Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome by Sclafani, F., Cascione, L., Cunningham, D., Young, K., Carotenuto, P., Fassan, M., Salati, M., Lanese, A., Berenguer Pina, J., Kouvelakis, K., Vendrell, I., Said-Huntingford, I., Previdi, M., Begum, R., Gillbanks, A., Hedayat, S., Sadanandam, A., Lampis, A., Hahne, J., Valeri, N., Chau, I., Braconi, C.

Get full text

Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study by Alouani, E., Mercier, M., Flecchia, C., Auclin, E., Hollebecque, A., Mazard, T., Turpin, A., Pernot, S., Cohen, R., Dutherage, M., Kim, S., Sclafani, F., Ben-Abdelghani, M., Herve, C., Aparicio, T., De La Fouchardière, C., Perkins, G., Hautefeuille, V., Jaffrelot, M., Gallois, C., Bongard, V., Tougeron, D., Taïeb, J., Guimbaud, R.

“…Immunotherapy demonstrated remarkable efficacy in metastatic colorectal cancers (mCRCs) with mismatch repair deficiency (MMRd)/microsatellite instability…”
Get full text

Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS) by R. Saúde-Conde, T. Vandamme, M. De Backer, P. Martinive, A. Covas, A. Deleporte, A. Dermine, F. Forget, K. Geboes, Q. Gilliaux, Y. Gokburun, E. Gonne, I. Joye, S. Lecomte, G. Liberale, W. Lybaert, L. Moretti, L. Mortier, S. Mupingu Mwanawa, F. Puleo, E.D. Saad, I. Sinapi, L. Annemans, M. Buyse, F. Sclafani

“…Although total neoadjuvant therapy (TNT) is a new standard of care for locally advanced rectal cancer (LARC), there are no data to confirm the safety and…”
Get full text

Session 2: Are we ready for primary chemotherapy in rectal cancer: who, when, why? by Patel, U. B., Cervantes, A., Fernández‐Martos, C., Sclafani, F., Cunningham, D., Nilsson, P., Brown, G.

“…The potential of preoperative chemotherapy in rectal cancer is the subject of investigation in a number of global randomized trials. In this overview and…”
Get full text

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective by Koessler, T., Alsina, M., Arnold, D., Ben-Aharon, I., Collienne, M., Lutz, M.P., Neuzillet, C., Obermannova, R., Peeters, M., Sclafani, F., Smyth, E., Valle, J.W., Wagner, A.D., Wyrwicz, L., Fontana, E., Moehler, M.

“…There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation…”
Get full text